glp 2tz vs tirzepatide Reta — what's actually different? Tirzepatide hits GLP-1 and GIP receptors. Reta hits GLP-1, GIP, and glucagon. That added glucagon activity is why you're seeing more aggressive fat loss claims Tirzepatide: A Promising Drug for

These include: Nausea (affecting 20-40% of patients initially) Vomiting Diarrhoea Constipation Abdominal discomfort These symptoms can be debilitating during the first few weeks of treatment and may cause fatigue, reduced appetite, and general malaise

Women with uterine fibroids are often estrogen dominant and have low progesterone levels (6)

Craig CM, Liu LF, Deacon CF, Holst JJ, McLaughlin TL

Some of this is likely attributable to the novelty of the triple mechanism, the higher efficacy driving more pronounced initial adaptation symptoms, and the fact that Phase 2 trial participants had less access to community experience about managing the adjustment period